Clinical Trials Browser

Active not recruiting × OTHER × ciforadenant × Clear all

NCT05501054 2026-01-14

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell